title: Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.
authors.forename: S
authors.initials: S
authors.lastname: Tyring
authors.forename: J
authors.initials: J
authors.lastname: Bagel
authors.forename: C
authors.initials: C
authors.lastname: Lynde
authors.forename: P
authors.initials: P
authors.lastname: Klekotka
authors.forename: E H Z
authors.initials: EH
authors.lastname: Thompson
authors.forename: S R
authors.initials: SR
authors.lastname: Gandra
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: G
authors.initials: G
authors.lastname: Kricorian
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012016:Reference Values; D012536:Scalp Dermatoses / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012647:Self-Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept